Literature DB >> 33671245

Cracking the Breast Cancer Glyco-Code through Glycan-Lectin Interactions: Targeting Immunosuppressive Macrophages.

Nuno Lopes1,2, Viviana G Correia3, Angelina S Palma3, Catarina Brito1,2.   

Abstract

The immune microenvironment of breast cancer (BC) is composed by high macrophage infiltrates, correlated with the most aggressive subtypes. Tumour-associated macrophages (TAM) within the BC microenvironment are key regulators of immune suppression and BC progression. Nevertheless, several key questions regarding TAM polarisation by BC are still not fully understood. Recently, the modulation of the immune microenvironment has been described via the recognition of abnormal glycosylation patterns at BC cell surface. These patterns rise as a resource to identify potential targets on TAM in the BC context, leading to the development of novel immunotherapies. Herein, we will summarize recent studies describing advances in identifying altered glycan structures in BC cells. We will focus on BC-specific glycosylation patterns known to modulate the phenotype and function of macrophages recruited to the tumour site, such as structures with sialylated or N-acetylgalactosamine epitopes. Moreover, the lectins present at the surface of macrophages reported to bind to such antigens, inducing tumour-prone TAM phenotypes, will also be highlighted. Finally, we will discuss and give our view on the potential and current challenges of targeting these glycan-lectin interactions to reshape the immunosuppressive landscape of BC.

Entities:  

Keywords:  aberrant glycosylation; breast cancer; glycan-lectin interactions; immunotherapy; tumour microenvironment; tumour-associated macrophages

Mesh:

Substances:

Year:  2021        PMID: 33671245      PMCID: PMC7922062          DOI: 10.3390/ijms22041972

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  102 in total

1.  High-mannose glycans are elevated during breast cancer progression.

Authors:  Maria Lorna A de Leoz; Lawrence J T Young; Hyun Joo An; Scott R Kronewitter; Jaehan Kim; Suzanne Miyamoto; Alexander D Borowsky; Helen K Chew; Carlito B Lebrilla
Journal:  Mol Cell Proteomics       Date:  2010-11-19       Impact factor: 5.911

Review 2.  The neoglycolipid (NGL)-based oligosaccharide microarray system poised to decipher the meta-glycome.

Authors:  Angelina S Palma; Ten Feizi; Robert A Childs; Wengang Chai; Yan Liu
Journal:  Curr Opin Chem Biol       Date:  2014-02-07       Impact factor: 8.822

Review 3.  Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family.

Authors:  Eric P Bennett; Ulla Mandel; Henrik Clausen; Thomas A Gerken; Timothy A Fritz; Lawrence A Tabak
Journal:  Glycobiology       Date:  2011-12-18       Impact factor: 4.313

Review 4.  Glycosylation and its implications in breast cancer.

Authors:  Danielle A Scott; Richard R Drake
Journal:  Expert Rev Proteomics       Date:  2019-07-25       Impact factor: 3.940

5.  Advances in molecular mechanisms of drugs affecting abnormal glycosylation and metastasis of breast cancer.

Authors:  Huimin Liu; Lele Ma; Junzhi Lin; Bo Cao; Duan Qu; Chuanhong Luo; Wei Huang; Li Han; Hong Xu; Zhenfeng Wu; Runchun Xu; Dingkun Zhang
Journal:  Pharmacol Res       Date:  2020-03-07       Impact factor: 7.658

Review 6.  Mouse models in oncoimmunology.

Authors:  Laurence Zitvogel; Jonathan M Pitt; Romain Daillère; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Cancer       Date:  2016-09-30       Impact factor: 60.716

7.  Tissue and serum MUC1 mucin detection in breast cancer patients.

Authors:  María V Croce; Marina T Isla-Larrain; Sandra O Demichelis; Jorge R Gori; Mike R Price; Amada Segal-Eiras
Journal:  Breast Cancer Res Treat       Date:  2003-10       Impact factor: 4.872

8.  Serum IgA1 shows increased levels of α2,6-linked sialic acid in breast cancer.

Authors:  Hannah J Lomax-Browne; Claire Robertson; Aristotelis Antonopoulos; Anthony J C Leathem; Stuart M Haslam; Anne Dell; Miriam V Dwek
Journal:  Interface Focus       Date:  2019-02-15       Impact factor: 3.906

Review 9.  3D In Vitro Model (R)evolution: Unveiling Tumor-Stroma Interactions.

Authors:  João Rodrigues; Marcel A Heinrich; Liliana Moreira Teixeira; Jai Prakash
Journal:  Trends Cancer       Date:  2020-11-18

Review 10.  Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer.

Authors:  Nicola Gaynor; John Crown; Denis M Collins
Journal:  Semin Cancer Biol       Date:  2020-07-02       Impact factor: 15.707

View more
  3 in total

1.  Patient-Derived Breast Cancer Tissue Cultures for Anti-Endocrine Drug Assays.

Authors:  Giacomo Domenici; Gonçalo Trindade; Marta F Estrada; Ana Luísa Cartaxo; Paula M Alves; Saudade André; Catarina Brito
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Targeting glycans for CAR therapy: The advent of sweet CARs.

Authors:  Zoe Raglow; Mary Kathryn McKenna; Challice L Bonifant; Wenjing Wang; Marina Pasca di Magliano; Johannes Stadlmann; Josef M Penninger; Richard D Cummings; Malcolm K Brenner; David M Markovitz
Journal:  Mol Ther       Date:  2022-07-12       Impact factor: 12.910

3.  Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis.

Authors:  Leiming Wang; Xi Yang; Fei Zhou; Xuesi Sun; Shulin Li
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.